Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

@article{Lublin2016OralFI,
  title={Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.},
  author={Fred D. Lublin and David H. Miller and M. S. Freedman and Bruce A. C. Cree and Jerry S. Wolinsky and Howard L. Weiner and Catherine Lubetzki and Hans-Peter Hartung and Xavier Montalban and Bernard M. J. Uitdehaag and Martin Merschhemke and Bingbing Li and Norman Putzki and Fonda C Liu and Dieter Adrian H{\"a}ring and Ludwig Kappos},
  journal={Lancet},
  year={2016},
  volume={387 10023},
  pages={1075-1084}
}
BACKGROUND No treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis, but has not been assessed in primary progressive multiple sclerosis. We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis. METHODS In INFORMS, a multicentre, double-blind, placebo-controlled parallel-group study, patients with primary… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies

Degenerative neurological and neuromuscular disease • 2017
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…